These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 38818288)

  • 1. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.
    Xie C; Alkhouri N; Elfeki MA
    World J Hepatol; 2024 May; 16(5):731-750. PubMed ID: 38818288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
    Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
    Ordóñez-Vázquez AL; Beltrán-Gall SM; Pal SC; Méndez-Sánchez N
    Med Sci Monit; 2022 Sep; 28():e938365. PubMed ID: 36093924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
    Harrison SA; Browne SK; Suschak JJ; Tomah S; Gutierrez JA; Yang J; Roberts MS; Harris MS
    J Hepatol; 2025 Jan; 82(1):7-17. PubMed ID: 39002641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Huttasch M; Roden M; Kahl S
    Metabolism; 2024 Aug; 157():155937. PubMed ID: 38782182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
    McGlone ER; Tan TM
    Peptides; 2024 Jun; 176():171219. PubMed ID: 38615717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of incretin receptor agonists in the treatment of obesity.
    Forst T; De Block C; Del Prato S; Armani S; Frias J; Lautenbach A; Ludvik B; Marinez M; Mathieu C; Müller TD; Schnell O
    Diabetes Obes Metab; 2024 Oct; 26(10):4178-4196. PubMed ID: 39072877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
    Newsome PN; Ambery P
    J Hepatol; 2023 Dec; 79(6):1557-1565. PubMed ID: 37562748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Choi E; Ramirez Tovar A; He Z; Soler Rodriguez DM; Vos MB; Arora S; Fadoju D
    Children (Basel); 2024 Feb; 11(3):. PubMed ID: 38539310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
    Hachuła M; Kosowski M; Basiak M; Okopień B
    Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.